{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:50:14Z","timestamp":1774561814250,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yebeh.2021.107935","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T09:54:05Z","timestamp":1619517245000},"page":"107935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes"],"prefix":"10.1016","volume":"119","author":[{"given":"Parveen","family":"Sagar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Wawryk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Vogrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Whitham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Carne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Lawn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armin","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-5131","authenticated-orcid":false,"given":"Wendyl Jude","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2021.107935_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.107935_b0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nrleng.2012.04.013","article-title":"Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study","volume":"28","author":"Villanueva","year":"2013","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"10.1016\/j.yebeh.2021.107935_b0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/jnnp-2013-307074","article-title":"Increased mortality persists in an adult drug-resistant epilepsy prevalence cohort","volume":"85","author":"Callaghan","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2021.107935_b0020","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eplepsyres.2014.12.001","article-title":"Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy","volume":"110","author":"Gao","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107935_b0025","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.107935_b0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate?","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.107935_b0035","doi-asserted-by":"crossref","unstructured":"Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. Perampanel: a novel, orally active, noncompetitive AMPA\u2010receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-340.","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"10.1016\/j.yebeh.2021.107935_b0040","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ane.12879","article-title":"Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings","volume":"137","author":"Tsai","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107935_b0045","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107935_b0050","doi-asserted-by":"crossref","unstructured":"French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25.","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"key":"10.1016\/j.yebeh.2021.107935_b0055","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107935_b0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2021.107935_b0065","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study","volume":"307","author":"Krauss","year":"2014","journal-title":"Epilepsy"},{"key":"10.1016\/j.yebeh.2021.107935_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yebeh.2014.09.072","article-title":"Clinical experience with perampanel: Focus on psychiatric adverse effects","volume":"41","author":"Coyle","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0080","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ane.12558","article-title":"Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience","volume":"134","author":"Juhl","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107935_b0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yebeh.2016.06.005","article-title":"Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in Tours","volume":"61","author":"Maurousset","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0090","first-page":"437","article-title":"Perampanel: An audit of clinical experience using the epilepsy electronic patient record","volume":"109","author":"Ryan","year":"2016","journal-title":"Irish Med J"},{"key":"10.1016\/j.yebeh.2021.107935_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2015.10.017","article-title":"Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study","volume":"34","author":"Shah","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107935_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yebeh.2016.05.007","article-title":"Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study","volume":"61","author":"Singh","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0105","doi-asserted-by":"crossref","unstructured":"Villanueva V, Garc\u00e9s M, L\u00f3pez-Gonz\u00e1lez FJ, Rodriguez-Osorio X, Toledo M, Salas-Puig J, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study. Epilepsy Res 2016;126:201-10.","DOI":"10.1016\/j.eplepsyres.2016.08.001"},{"key":"10.1016\/j.yebeh.2021.107935_b0110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2016.10.020","article-title":"A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment","volume":"66","author":"Huber","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.seizure.2017.05.012","article-title":"Perampanel in the general population and in people with intellectual disability: differing responses","volume":"49","author":"Shankar","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107935_b0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.yebeh.2017.04.006","article-title":"Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center","volume":"73","author":"Wehner","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2021.107935_b0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.seizure.2019.04.013","article-title":"Perampanel for the treatment of epilepsy; longitudinal actuarial analysis and dose responses based on monthly outcomes","volume":"69","author":"Stavropoulos","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107935_b0135","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0140","doi-asserted-by":"crossref","unstructured":"Moraes J, Hepworth G, Ignatidis S, Dharan A, Carne R, Seneveritne U, et al. Improved irritability, mood and quality of life following introduction of perampanel as late-adjunctive treatment for epilepsy In: Department of Medicine SVsHM, The University of Melbourne, editor. Epilepsy Behav; 2020;104:106883.","DOI":"10.1016\/j.yebeh.2019.106883"},{"key":"10.1016\/j.yebeh.2021.107935_b0145","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0150","doi-asserted-by":"crossref","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"10.1016\/j.yebeh.2021.107935_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yebeh.2017.11.027","article-title":"Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs","volume":"80","author":"Neal","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1740774515602688","article-title":"Fallacies of last observation carried forward analyses","volume":"13","author":"Lachin","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.yebeh.2021.107935_b0165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.yebeh.2021.107935_b0170","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(18)30274-6","article-title":"Circadian and circaseptan rhythms in human epilepsy: a retrospective cohort study","volume":"17","author":"Karoly","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107935_b0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40261-014-0255-5","article-title":"Early add-on lacosamide in a real-life setting: results of the REALLY study","volume":"35","author":"Villanueva","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.yebeh.2021.107935_b0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13059","article-title":"BRIVA-LIFE\u2013A multicenter retrospective study of the long-term use of brivaracetam in clinical practice","volume":"139","author":"Villanueva","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2021.107935_b0185","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/epi.16476","article-title":"Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs","volume":"61","author":"Thieffry","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.seizure.2016.11.012","article-title":"Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies \u2013 A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center","volume":"45","author":"Kurth","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2021.107935_b0195","doi-asserted-by":"crossref","unstructured":"Liguori C, Manfredi N, Renna R, Izzi F, Pagliuca M, Pagliuca F, et al. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study. Epileptic Disord 2020;22:309-16.","DOI":"10.1684\/epd.2020.1165"},{"key":"10.1016\/j.yebeh.2021.107935_b0200","doi-asserted-by":"crossref","first-page":"106883","DOI":"10.1016\/j.yebeh.2019.106883","article-title":"Improved irritability, mood, and quality of life following introduction of perampanel as late adjunctive treatment for epilepsy","volume":"104","author":"Moraes","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0205","doi-asserted-by":"crossref","unstructured":"Garamendi-Ruiz I, Garc\u00eda-Garc\u00eda ME, Bertol-Alegre V, Mauri-Llerda J\u00c1, Garc\u00eda-Morales I, Garayoa-Irigoyen V, et al. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability. Epileptic Disord 2016;18:173-80.","DOI":"10.1684\/epd.2016.0824"},{"key":"10.1016\/j.yebeh.2021.107935_b0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000222775","article-title":"Refractory epilepsy: A clinically oriented review","volume":"62","author":"Beleza","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2021.107935_b0215","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.yebeh.2017.06.008","article-title":"Persistence with antiepileptic drugs in epilepsy patients treated in neurological practices in Germany","volume":"73","author":"Jacob","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107935_b0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(12)70018-2","article-title":"Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial","volume":"11","author":"Bonnett","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107935_b0225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/epi.16765","article-title":"Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?","volume":"62","author":"Janmohamed","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0230","doi-asserted-by":"crossref","unstructured":"Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010;51:797-804.","DOI":"10.1111\/j.1528-1167.2010.02520.x"},{"key":"10.1016\/j.yebeh.2021.107935_b0235","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0240","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107935_b0245","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/epi.13435","article-title":"Seizure outcome after switching antiepileptic drugs: A matched, prospective study","volume":"57","author":"Finamore","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107935_b0250","unstructured":"Sills GJ. Mechanisms of action of antiepileptic drugs In: Smalls FR-GaJ, editor. From channels to commissioning - a practical guide to epilepsy: International League Against Epilepsy and Epilepsy Society; 2015."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:39:56Z","timestamp":1761503996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":50,"alternative-id":["S1525505021001694"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107935","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107935"}}